A mother’s mitochondria determines if lactation is protective or not against breast cancer—and points to a possible intervention to increase the benefit to more women, according to a pre-clinical study conducted by researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.
